{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:24:31Z","timestamp":1783718671845,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95159"],"award-info":[{"award-number":["N01-HC-95159"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95160"],"award-info":[{"award-number":["N01-HC-95160"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95168"],"award-info":[{"award-number":["N01-HC-95168"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95166"],"award-info":[{"award-number":["N01-HC-95166"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95169"],"award-info":[{"award-number":["N01-HC-95169"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95163"],"award-info":[{"award-number":["N01-HC-95163"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HHSN268201500003I"],"award-info":[{"award-number":["HHSN268201500003I"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95161"],"award-info":[{"award-number":["N01-HC-95161"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95162"],"award-info":[{"award-number":["N01-HC-95162"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95165"],"award-info":[{"award-number":["N01-HC-95165"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95167"],"award-info":[{"award-number":["N01-HC-95167"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95164"],"award-info":[{"award-number":["N01-HC-95164"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1122854"],"award-info":[{"award-number":["1122854"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["100715"],"award-info":[{"award-number":["100715"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR-000040"],"award-info":[{"award-number":["UL1-TR-000040"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR-001420"],"award-info":[{"award-number":["UL1-TR-001420"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1-TR-001079"],"award-info":[{"award-number":["UL1-TR-001079"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.atherosclerosis.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T12:43:51Z","timestamp":1584362631000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"299","author":[{"given":"Bradley","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn L.","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Budoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Barter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry-Anne","family":"Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok Leung","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib2","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib5","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/cen.12095","article-title":"Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives","volume":"78","author":"Woo","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib8","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib9","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2015.11.012","article-title":"Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-\u03b2\/smad2\/3 and NF-\u03baB signaling pathways","volume":"290","author":"Xu","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jhep.2012.10.029","article-title":"High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China","volume":"58","author":"Li","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib13","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.diabres.2011.02.034","article-title":"Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently","volume":"93","author":"Li","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH \u2014 current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2018.10.011","article-title":"Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: the Multi-Ethnic Study of Atherosclerosis","volume":"281","author":"Ong","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1373\/clinchem.2016.270876","article-title":"Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: results from the FIELD study","volume":"63","author":"Ong","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib19","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-ethnic study of atherosclerosis: objectives and design","volume":"156","author":"Bild","year":"2002","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.gheart.2016.09.001","article-title":"The multiethnic study of atherosclerosis","volume":"11","author":"Burke","year":"2016","journal-title":"Global Heart"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2017.12.026","article-title":"The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis","volume":"269","author":"Hui","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib23","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1210\/jc.2012-2267","article-title":"Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes","volume":"97","author":"Ong","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.acra.2012.02.022","article-title":"Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis","volume":"19","author":"Zeb","year":"2012","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.atherosclerosis.2015.02.011","article-title":"The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"239","author":"Al Rifai","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/radiol.2391050361","article-title":"Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment","volume":"239","author":"Park","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cca.2017.11.002","article-title":"Fibroblast growth factor 21 in chronic kidney disease","volume":"489","author":"Anuwatmatee","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2217\/bmm.13.71","article-title":"Associations between total serum GGT activity and metabolic risk: MESA","volume":"7","author":"Bradley","year":"2013","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib31","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib32","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib33","article-title":"Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese","volume":"6","author":"Lin","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib34","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.metabol.2010.03.018","article-title":"Serum fibroblast growth factor\u201321 concentration is associated with residual renal function and insulin resistance in end-stage renal disease patients receiving long-term peritoneal dialysis","volume":"59","author":"Han","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib35","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/en.2012-1193","article-title":"TNF-\u03b1 represses \u03b2-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway","volume":"153","author":"D\u00edaz-Delf\u00edn","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib36","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1210\/jc.2008-2331","article-title":"Serum fibroblast growth factor 21 is associated with adverse lipid profiles and \u03b3-glutamyltransferase but not insulin sensitivity in Chinese subjects","volume":"94","author":"Li","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.ATV.18.7.1046","article-title":"Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease","volume":"18","author":"Freedman","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","article-title":"Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis","volume":"227","author":"DeFilippis","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib39","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1210\/jc.2015-2649","article-title":"Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men","volume":"100","author":"Pramfalk","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.153994","article-title":"Fibroblast growth factor 21 in non-alcoholic fatty liver disease","volume":"101","author":"Tucker","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib41","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib42","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jhep.2011.12.025","article-title":"Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers","volume":"56","author":"Shen","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/srep30484","article-title":"Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL\/6J mice","volume":"6","author":"Rusli","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004424-199304000-00006","article-title":"Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography","volume":"28","author":"Longo","year":"1993","journal-title":"Invest. Radiol."},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib45","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.atherosclerosis.2020.03.009_bib46","doi-asserted-by":"crossref","first-page":"g4596","DOI":"10.1136\/bmj.g4596","article-title":"Non-alcoholic fatty liver disease","volume":"349","author":"Sattar","year":"2014","journal-title":"BMJ"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020301453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020301453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:08:01Z","timestamp":1778645281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020301453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":46,"alternative-id":["S0021915020301453"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.03.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}